MOTS-c protocol pages promise a schedule for a person. The protocols that actually exist in the literature were written for mice and for cells in a dish. The one human protocol everybody cites turns out to be a registry entry with no study behind it. Reading them in order makes the gap between the research and the retail version obvious, because the research never asked the question the retail version answers.
The vendor we point lifters to
MOTS-c from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
Buying 3, 5 or 10 vials takes 3%, 5% or 10% off the list price. Free shipping starts at $250, which one discounted vial does not reach.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 19, 2026.
Start with what was run, on what, and to measure what.
The MOTS-c protocol record, study by study
| Study type | What the design involved | Outcome measured | Organism |
|---|---|---|---|
| Metabolic feeding studies | Repeated administration alongside a controlled diet | Body weight, glucose handling, insulin sensitivity | Mouse |
| Mechanistic pathway work | Exposure of cells in culture | Folate and one carbon cycle activity, AMPK activation | Cell culture |
| Ageing performance work | Administration to old animals, treadmill testing | Running capacity and physical performance measures | Aged mouse |
| Exercise response measurement | Blood and muscle sampling around exercise | Endogenous peptide levels | Human, observational |
| Population genetics | Variant frequency and association analysis | Association with longevity and exercise traits | Human, observational |
Five rows, and the important feature is what the third column never contains. No design in this literature measured muscle mass, cross sectional area, hypertrophy or strength, in any species. The outcomes are metabolic and, in one case, endurance in old rodents.
Inside a rodent metabolic experiment
The phrase "studies show" hides a very particular set of conditions, and knowing them changes how much weight a finding carries.
A mouse metabolic study uses animals that are genetically near identical, housed under fixed light cycles, fed a defined diet, and not exercising in any way a lifter would recognise. Diet induced obesity models feed a high fat diet deliberately to create the metabolic problem the compound is then tested against. Administration is by injection on a fixed schedule chosen by the investigators, and the endpoint is measured under standardised conditions, usually a glucose tolerance test, tissue analysis, or body weight on a controlled intake.
Within that design, mouse studies have reported that MOTS-c improves glucose handling and limits diet induced weight gain. That is a real finding and it is a finding about mice with an induced metabolic problem.
Three things do not carry across to a person. The metabolic deficit was manufactured, so the improvement is partly a correction of the model. The animals are not training, so no interaction with a training stimulus was tested. And a mouse clears a peptide and burns fuel at rates a human does not approach, which is why milligram arithmetic between species is an estimate rather than a translation.
The ageing performance work, described accurately
The rodent study quoted most often on a site like this is the ageing one, where old mice given the peptide have been reported to improve on running capacity and related physical performance measures.
Its shape deserves stating plainly. Aged animals, a period of administration, then standardised testing on a treadmill and on physical function tasks, compared against untreated animals of the same age. The outcome is endurance and general capacity, not tissue size.
Two readings follow and only one is supported. It is fair to say the result is consistent with a metabolic effect showing up as function in old animals, which is genuinely interesting. It is not fair to convert it into hypertrophy, into strength, or into anything about a trained person, because none of that was measured and a mouse on a treadmill is not someone training deliberately against a load.
The human protocol that is not a protocol
Every page on this compound points at the same record when it claims a human protocol exists. It is listed as Phase 2, names an enrolment figure, describes adults with prediabetes and overweight or obesity, gives insulin sensitivity as the endpoint and reads as recruiting. Confirming that the identifier NCT07505745 resolves returns all of it cleanly, which is where most checking stops.
The sponsor field is where it comes apart. The record shares a lead sponsor with seven others submitted to the same registry between February and April 2026. All are listed as recruiting. All name one hospital site. Between them they cover a catalogue of compounds sold to this audience rather than a research theme: repair and healing peptides, a tanning compound, a copper complex, a growth hormone releasing analogue and two weight loss drugs. One of the seven states in its own brief summary that it is a fictional example of a registry style record. The sponsor has no application on file with the FDA and nothing published under its name.
That changes what this section can honestly say. There is no registered human protocol for MOTS-c. There is a registry entry with the shape of one, and the parameters listed in it were typed into a submission form rather than run in a clinic.
The distinction matters more on this page than on most, because a protocol is precisely the object under discussion. A real protocol is a commitment made in public before the answer is known: a defined population, a dose, a route, a duration, a prespecified endpoint, ethics approval, and a site that has to enrol actual people and account for what happens to them. It constrains the investigators, which is the entire reason registration exists. A record with those fields filled in constrains nobody, and copying its dose and duration into a personal plan borrows the authority of a study that was never run.
Registry searches return studies that have nothing to do with it
This is where numbers get invented without anyone intending to lie. A search on a trial registry matches a term anywhere in a record, including in eligibility text and outcome descriptions, so a search for this peptide returns studies about anaesthesia, vestibular implants, and exercise programmes in cancer and dialysis populations.
Somebody counts the hits and writes that there are several registered trials. The count is real and the conclusion is false. Reading the titles collapses the list to a single record, and reading that record's sponsor field collapses it to nothing.
That is why claims about this compound should be checked against records rather than counts, and why there is no trial number worth quoting for MOTS-c at all.
What none of these designs measured
Worth restating in one place, because it is the answer to the question this site's readers actually have.
No published MOTS-c protocol measured muscle protein synthesis, in any organism. None measured myostatin pathway activity. None used lean body mass or fat free mass as an endpoint. None tested the peptide in trained subjects, and none tested it alongside a resistance training programme in any species.
The nearest thing to a performance protocol is the ageing work in mice, where treated old animals have been reported to improve on running capacity. Endurance capacity in aged rodents is a legitimate result and a poor proxy for hypertrophy in a person who lifts.
So the literature is not negative on muscle. It is silent, and silence is easy to mistake for permission.
There is a related absence worth naming for readers over forty. No published protocol tested this peptide in older adults, which is the group in whom the mitochondrial decline that makes the compound interesting is most pronounced. The ageing work is in mice. The human work is observational measurement of the body's own levels around a training session. The overlap with an ageing lifter is small in both directions.
Checking a registry claim in about a minute
The record above got quoted here and nearly everywhere else because the check people run stops one field too early. The longer version is short enough that anybody can run it, and it works on every compound sold to this audience.
Open the record on the registry itself rather than on the page that cited it. Read the lead sponsor. A university, a hospital network, a national funding body or a company with a history behind it is one thing. A sponsor name that returns nothing anywhere except this record is another, so search it separately: a real sponsor running a Phase 2 study leaves other traces, in regulatory filings, in published work, in the existence of the company.
Read the brief summary all the way to the end. It is written by whoever submitted the record, and submitters who are not running a study sometimes say so plainly, in a paragraph nobody scrolls to.
Look at the sites. A single site for a large multi arm study is unusual on its own. The same single site attached to several unrelated records from one sponsor is a pattern rather than a coincidence.
Then check the posting dates across that sponsor's other records. A cluster of registrations appearing within a few weeks of each other, covering compounds that share nothing except a retail catalogue, describes a submission run rather than a research programme.
None of that needs paid access or specialist knowledge. It needs four fields the identifier itself does not contain, which is the whole lesson: a number records a registration, not a result, and a registry that accepts submissions is not a body that verifies them.
Questions the protocol record raises
Is there a published human protocol for MOTS-c?
No. The record usually cited as one shares a lead sponsor with a set of sibling entries covering unrelated compounds, one of which declares itself fictional in its own summary. No genuine human protocol for this peptide has been registered or published.
Can the mouse schedule be scaled to a person?
Not reliably. Interspecies conversion is an estimating rule for planning early human studies, and the underlying rodent experiments measured metabolic outcomes in sedentary animals with an induced metabolic problem.
Did any study combine the peptide with training?
No published study in any species administered MOTS-c alongside a structured training programme.
Why do some articles cite several trials?
Because they counted keyword search hits without reading the records. The additional hits are unrelated studies that happen to mention the term, and the one record that does name the peptide does not survive a look at its sponsor.
What would a protocol relevant to this site look like?
Controlled administration in trained humans, with lean mass or strength as a stated endpoint, measured by a method with known error, and results published. No such study has been registered.
Where that leaves a reader
The protocol record is coherent and it is small. A mitochondrial derived peptide, studied in mice and cells for its effects on fuel handling, observed in humans to rise with exercise, and not yet the subject of a single genuine human trial.
That is a defensible reason to follow the research. It is not a schedule, and anyone presenting it as one has filled the gaps with material the studies do not contain. For ageing muscle, the protocols with human outcome data behind them remain the ones nobody sells: progressive resistance work the joints tolerate over years, protein high enough to matter, sleep, and enough continuity that training blocks stay intact.